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Abstract
Introduction: Thrombin is a key factor in the stimulation of fibrin deposition, angiogenesis, and proinflammatory
processes. Abnormalities in these processes are primary features of osteoarthritis (OA). Heme oxygenase (HO)-1 is a
stress-inducible rate-limiting enzyme in heme degradation that confers cytoprotection against oxidative injury.
Here, we investigated the intracellular signaling pathways involved in thrombin-induced HO-1 expression in human
synovial fibroblasts (SFs).
Methods: Thrombin-mediated HO-1 expression was assessed with quantitative real-time (q)PCR. The mechanisms
of action of thrombin in different signaling pathways were studied by using Western blotting. Knockdown of
protease-activated receptor (PAR) proteins was achieved by transfection with siRNA. Chromatin
immunoprecipitation assays were used to study in vivo binding of Nrf2 to the HO-1 promoter. Transient
transfection was used to examine HO-1 activity.
Results: Osteoarthritis synovial fibroblasts (OASFs) showed significant expression of thrombin, and expression was
higher than in normal SFs. OASFs stimulation with thrombin induced concentration- and time-dependent increases
in HO-1 expression. Pharmacologic inhibitors or activators and genetic inhibition by siRNA of protease-activated
receptors (PARs) revealed that the PAR1 and PAR3 receptors, but not the PAR4 receptor, are involved in thrombin-
mediated upregulation of HO-1. Thrombin-mediated HO-1 expression was attenuated by thrombin inhibitor
(PPACK), PKCδ inhibitor (rottlerin), or c-Src inhibitor (PP2). Stimulation of cells with thrombin increased PKCδ, c-Src,
and Nrf2 activation.
Conclusion: Our results suggest that the interaction between thrombin and PAR1/PAR3 increases HO-1 expression
in human synovial fibroblasts through the PKCδ, c-Src, and Nrf2 signaling pathways.
Introduction
Osteoarthritis (OA) is a degenerative disease character-
ized by a slow progressive degeneration of articular car-
tilage, variable secondary synovial inflammation, and
osteophyte formation [1,2]. The exact etiology of OA is
not well understood. In response to macrophage-derived
proinflammatory cytokines, such as interleukin (IL)-1b
and tumor necrosis factor-a (TNF)-a, OA synovial
fibroblasts (OASFs) produce chemokines that promote
inflammation, neovascularization, and cartilage degrada-
tion through activation of matrix-degrading enzymes
such as matrix metalloproteinases (MMPs) [3].
Heme oxygenase (HO)-1 is the key enzyme responsible
for the degradation of heme to carbon monoxide, free
iron, and biliverdin-IX [4]. In mammals, biliverdin-IX is
further converted to bilirubin-IX, an endogenous radical
scavenger with recently recognized antiinflammatory
properties [5]. Free iron is rapidly sequestered into the
iron-storage protein ferritin, leading to additional antiox-
idant and antiapoptotic effects [6]. Carbon monoxide
serves several biologic functions, with antiapoptotic and
antiinflammatory properties [7]. HO-1 is induced by
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various stimuli, such as lipopolysaccharide (LPS), proin-
flammatory cytokines, and oxidants [8,9]. Recent findings
revealed that HO-1 induction in animals protects them
against the development of arthritis [10]. HO-1 induction
in OA chondrocytes results in decreased levels of MMPs
and can exert protective effects against cartilage degrada-
tion [11]. In synovial cells, HO-1 is an important factor
regulating inflammation and cartilage degradation during
OA [12]. Therefore, HO-1 plays a crucial role in OA
pathogenesis. However, the role of thrombin in HO-1
expression in OA is still unknown.
Thrombin is a multifunctional enzyme that can activate
hemostasis and coagulation through the cleavage of fibri-
nogen to form fibrin clots. Tissue damage and fibrin
deposition are common features of inflamed synovium in
OA, which indicates generation of thrombin in the
lesions and suggests an involvement of thrombin in the
joint inflammation [13]. Thrombin also acts as a mitogen
to stimulate the abnormal proliferation of synovial cells
during rheumatoid arthritis (RA) and OA pathogenesis
[14,15]. Thrombin activates intracellular signaling path-
ways by interacting with transmembrane domain G pro-
tein-coupled receptors, known as protease-activated
receptors (PARs). PARs have been implicated in the
development of acute and chronic inflammatory
responses. Three PARs, PAR-1, PAR-3, and PAR-4, are
cleaved by thrombin, whereas PAR-2 is cleaved by tryp-
sin. It has been reported that thrombin induces HO-1
release in human microglia [16], indicating that thrombin
may play a role in the regulation of specific gene expres-
sion, such as that of HO-1. However, the effect of throm-
bin on HO-1 expression in human synovial fibroblasts
has not yet been elucidated. In the present study, we
explored the intracellular signaling pathways involved in
thrombin-induced HO-1 expression in human OASFs. In
our experiment, thrombin activated the PAR1/PAR3
receptor, PKCδ, c-Src, and Nrf2 pathways, leading to the
upregulation of HO-1 expression. These results provide
new insights into the mechanisms of thrombin action
that may be of therapeutic value for OA.
Materials and methods
Materials
Protein A/G beads, anti-mouse and anti-rabbit IgG-con-
jugated horseradish peroxidase, rabbit polyclonal antibo-
dies specific for thrombin, PAR1, PAR3, PAR4, c-Src,
PKCδ, and Nrf2, and siRNA against PAR1, PAR3, and
PAR4 were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Rabbit polyclonal antibody speci-
fic for c-Src phosphorylated at Tyr416 and PKCδ phos-
phorylated at Tyr331 were purchased from Cell Signaling
and Neuroscience (Danvers, MA, USA). Rabbit polyclo-
nal antibody specific for Nrf2 phosphorylated at Ser40
was purchased from Abcam Inc. (Cambridge, MA, USA).
SFLLRN-NH2 (a PAR1-agonist peptide), TFRGAP-NH2
(a PAR3-agonist peptide), and GYPGQV-NH2 (a PAR4-
agonist peptide) were purchased from Bachem. Rottlerin,
GF109203X, Ro320432, and PP2 were purchased from
Calbiochem (Darmstadt, Germany). The c-Src dominant-
negative mutant was a gift from Dr. S. Parsons (Univer-
sity of Virginia Health System, Charlottesville, VA, USA).
The human HO-1 promoter construct was gift from Dr.
Y.C. Liang (Taipei Medical University, Taipei, Taiwan).
The pSV- b-galactosidase vector and luciferase assay kit
were purchased from Promega (Madison, WI, USA). All
other chemicals were purchased from Sigma-Aldrich (St.
Louis, MO, USA).
Cell cultures
We obtained approval from the local ethics committee,
and subjects gave informed written consent. Human
synovial fibroblasts were isolated by collagenase treat-
ment of synovial tissue samples obtained from 32
patients with OA during knee-replacement surgeries and
18 samples of nonarthritic synovial tissues obtained at
arthroscopy after trauma/joint derangement. The con-
centration of thrombin in the synovial fluid of selected
patients was measured with an enzyme-linked immuno-
sorbent assay (ELISA) according to the protocol provided
by the manufacturer (Human thrombin ELISA kit;
Abcam). OASFs were isolated, cultured, and character-
ized, as previously described [17,18]. Experiments were
performed by using cells from passages 3 to 6.
Quantitative real-time PCR
Total RNA was extracted from synovial fibroblasts by
using a TRIzol kit (MDBio Inc., Taipei, Taiwan). The
reverse-transcription reaction was performed by using 2
μg of total RNA that was reverse transcribed into cDNA
by using oligo (dT) primer [19,20]. The quantitative
real-time PCR (qPCR) analysis was carried out by using
Taqman one-step PCR Master Mix (Applied Biosystems,
Foster City, CA, USA). cDNA templates (2 μl) were
added per 25-μl reaction with sequence-specific primers
and Taqman probes. Sequences for all target gene pri-
mers and probes were purchased commercially (b-actin
was used as internal control) (Applied Biosystems). The
qPCR assays were carried out in triplicate on a StepO-
nePlus sequence-detection system. The cycling condi-
tions involved 10-minute polymerase activation at 95°C,
followed by 40 cycles at 95°C for 15 seconds and 60°C
for 60 seconds. The threshold was set above the non-
template control background and within the linear
phase of the target gene amplification to calculate the
cycle number at which the transcript was detected
(denoted CT).
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Western blot analysis
Cellular lysates were prepared as described previously
[21,22]. Proteins were resolved on SDS-PAGE and trans-
ferred to Immobilon polyvinyldifluoride (PVDF) mem-
branes. The blots were blocked with 4% BSA for 1 hour
at room temperature and then probed with rabbit anti-
human antibodies against PKCδ, c-Src, or Nrf2 (1:1,000)
for 1 hour at room temperature. After three washes, the
blots were subsequently incubated with donkey anti-rab-
bit peroxidase-conjugated secondary antibody (1:3,000)
for 1 hour at room temperature. The blots were visua-
lized by enhanced chemiluminescence with Kodak
X-OMAT LS film (Eastman Kodak, Rochester, NY, USA).
Transfection and reporter gene assay
Human synovial fibroblasts were co-transfected with
0.8 μg HO-1-luciferase plasmid and 0.4 μg b-galactosidase
expression vector. Fibroblasts were grown to 80% conflu-
ence in 12-well plates and were transfected the following
day with Lipofectamine 2000 (LF2000; Invitrogen). DNA
and LF2000 were premixed for 20 minutes and then
applied to cells. After 24-hour transfection, cells were
incubated with the indicated agents. After further 24-hour
incubation, the media were removed, and cells were
washed once with cold PBS. To prepare lysates, 100 μl of
reporter lysis buffer (Promega, Madison, WI, USA) was
added to each well, and cells were scraped from dishes.
The supernatant was collected after centrifugation at
13,000 rpm for 2 minutes. Aliquots of cell lysates (20 μl)
containing equal amounts of protein (20 to 30 μg) were
placed into wells of an opaque black 96-well microplate.
An equal volume of luciferase substrate was added to all
samples, and luminescence was measured in a microplate
luminometer. The value of luciferase activity was normal-
ized to transfection efficiency monitored by the co-trans-
fected b-galactosidase expression vector [23].
Kinase-activity assay
PKCδ activity was assessed with a PKCδ Kinase Activity
Assay Kit according to manufacturer’s instructions (Assay
Designs, MI, USA). The PKCδ activity kit is based on a
solid-phase ELISA that uses a specific synthetic peptide as
a substrate for PKCδ and a polyclonal antibody that recog-
nizes the phosphorylated form of the substrate.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) analysis was per-
formed as described previously [24]. DNA immunopreci-
pitated by anti-Nrf2 antibody was purified. The DNA was
then extracted with phenol-chloroform. The purified DNA
pellet was subjected to PCR. PCR products were then
resolved by using 1.5% agarose gel electrophoresis and
visualized with UV. The primers: 5’-CCATCAAACTT-
TAACTCGGTGA-3’ and 5’- GACTTGGGAGATAGAA
GGAACG-3’ were used to amplify across the human HO-
1 promoter region (-857 to -752) [24].
Statistics
The values are reported as mean ± SEM. Statistical analy-
sis between two samples was performed by using the Stu-
dent t test. Statistical comparisons of more than two
groups were performed by using one-way analysis of var-
iance (ANOVA) with the Bonferroni post hoc test. In all
cases, P < 0.05 was considered significant.
Results
Thrombin induces HO-1 expression in human synovial
fibroblasts
It has been reported that clotting factors and fibrinolytic
products are increased in synovial fluid of patients with
RA and OA [25]. Therefore, we examined the levels of
thrombin expression in samples from patients with OA
and found that the expression of thrombin protein in
human OASFs (Figure 1A, lines 4 to 6) was significantly
higher than that in normal SFs (Figure 1A, lines 1 to 3).
The OASFs medium showed a level of expression of
thrombin that was significantly higher than that seen in
the medium from normal SFs (Figure 1B). In addition,
concentrations of thrombin in synovial fluid were signifi-
cantly higher in patients with OA than in controls (Figure
1B). We applied thrombin directly to OASFs to examine
the expression of HO-1. Treatment of OASFs with throm-
bin (0.1 to 3 U/ml) for 24 hours induced HO-1 expression
in a concentration-dependent manner (Figure 1C, E), and
this induction occurred in a time-dependent manner
(Figure 1D, F). After thrombin (3 U/ml) treatment for
24 hours, the amount of HO-1 expression had increased
in OASFs (Figure 1D, F). To confirm further this stimula-
tion-specific mediation by thrombin, PPACK, a thrombin
inhibitor, was used. Pretreatment of cells with PPACK
effectively antagonized the potentiating effect of thrombin
on HO-1 expression (Figure 2A). These data indicated
that thrombin increases HO-1 expression in human
OASFs.
Involvement of PAR1/PAR3 receptor in thrombin-
mediated increase of HO-1 expression
Thrombin exerts its effects through interaction with speci-
fic PAR1, PAR 3, and PAR4 receptors [26]. To investigate
the role of PAR1, PAR3, and PAR4 subtype receptors in
thrombin-mediated increase of HO-1 expression, cells
were treated with PAR1-, 3-, and 4-specific agonist pep-
tides and then examined for expression levels of HO-1. Of
the agonist peptides tested, the PAR1-selective receptor
agonist peptide, SFLLRN-NH2 (100 μM) and TFRGAP-
NH2 (PAR3 agonist peptide; 100 μM) significantly
increased the expression of HO-1 (Figure 2A). In contrast,
GYPGQV-NH2 (PAR4 agonist peptide; 100 μM) failed to
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Figure 1 Thrombin induces HO-1 expression in human synovial fibroblasts. (A) Total protein was extracted from normal synovial fibroblasts
(lines 1 and 2) and osteoarthritis synovial fibroblast (OASF) cells (lines 3 to 6), and subjected to Western blot analysis for thrombin. (B; left
panel) Human synovial fibroblasts were cultured for 48 hours, and media were collected to measure thrombin. (B; right panel) Synovial fluid
was obtained from normal (n = 10) or osteoarthritis patients (n = 15) and examined with ELISA for the expression of thrombin. OASFs (six OA
lines) were incubated with various concentrations of thrombin for 24 hours (C, E) or with thrombin (3 U/ml) for 6, 12, or 24 hours (D, F). The
HO-1 expression was examined with Western blotting and qPCR. Results are expressed as the mean ± SEM. *P < 0.05 as compared with basal
level. #P < 0.05 as compared with the thrombin-treated group.
Figure 2 Involvement of PAR1 and PAR3 receptor in thrombin-induced HO-1 expression. (A) Osteoarthritis synovial fibroblasts (OASFs) (six
OA lines) were treated with thrombin (3 U/ml), thrombin plus PPACK (30 nM), SFLLRN-NH2 (100 μM), TFRGAP-NH2 (100 μM), and GYPGQV-NH2
(100 μM) for 24 hours, and HO-1 expression was examined with qPCR. (B) Normal synovial fibroblasts (seven normal lines) were treated with
thrombin (3 U/ml), SFLLRN-NH2 (100 μM), and TFRGAP-NH2 (100 μM) for 24 hours, and HO-1 expression was examined with qPCR. (C) Cells were
transfected with PAR1, PAR3, PAR4, or control siRNA for 24 hours, and PAR receptor level was examined with Western blotting. (D, E) Cells (five
OA lines) were transfected with PAR1, PAR3, PAR4, or control siRNA for 24 hours followed by stimulation with thrombin for 24 hours, and HO-1
expression was examined with Western blotting and qPCR. Results are expressed as the mean ± SEM. *P < 0.05 as compared with basal level. #P
< 0.05 as compared with thrombin-treated group.
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upregulate HO-1 expression. Furthermore, thrombin,
SFLLRN-NH2, and TFRGAP-NH2 only slightly increased
HO-1 expression in normal synovial fibroblasts (Figure
2B), indicating that PAR agonist-induced HO-1 expression
is more important during OA pathogenesis. To confirm
that PAR1 and PAR3 subtype receptors are involved in the
thrombin-mediated increase of HO-1 expression, specific
inhibition of PAR-receptor expression was accomplished
with siRNA (Figure 2C). It was found that PAR1 and
PAR3 receptor-specific siRNA but not PAR4-receptor
siRNA significantly blocked the thrombin-mediated
increase of HO-1 expression (Figure 2D, E), indicating
that interactions between thrombin and PAR1/PAR3 are
important for HO-1 expression in human OASF cells.
The signaling pathways of PKCδ and c-Src are involved in
the potentiating action of thrombin
PKC has been shown to play an important role in cellular
functions modulated by several stimuli, including thrombin
[27,28]. To determine whether PKC isoforms were involved
in thrombin-triggered HO-1 expression, OASFs were pre-
treated for 30 minutes with either GF109203X, a pan-PKC
inhibitor, or rottlerin, a selective PKCδ inhibitor [29], and
then incubated with thrombin for 24 hours. As shown in
Figure 3A and 3C, pretreatment with GF109203X and rot-
tlerin but not PKCa inhibitor (Ro320432, 10 μM) reduced
thrombin-induced HO-1 expression, which suggests that
PKCδ plays a specific role in thrombin-induced HO-1
expression in OASFs. Transfection of cells with PKCδ
Figure 3 PKCδ is involved in thrombin-induced HO-1 expression in synovial fibroblasts. (A, C) Osteoarthritis synovial fibroblasts (OASFs)
(six OA lines) were pretreated for 30 minutes with GF109203X (3 μM), rottlerin (10 μM), and Ro320432 (10 μM) followed by stimulation with
thrombin for 24 hours, and HO-1 expression was examined with Western blotting and qPCR. (B) Cells (seven OA lines) were transfected for 24
hours with PKCδ siRNA followed by stimulation with thrombin for 24 hours, and HO-1 expression was examined with qPCR. (C) Cells (six OA
lines) were incubated with thrombin for indicated time intervals, and PKCδ phosphorylation was examined with Western blotting. (D, E) Cells
(seven OA lines) were incubated with thrombin for 30 minutes or pretreated for 30 minutes with PPACK or transfected 24 hours with PAR1 and
PAR3 siRNA, followed by stimulation with thrombin for 30 minutes, and PKCδ kinase activity was determined with the PKCδ kinase kit. Results are
expressed as the mean ± SEM. *P < 0.05 as compared with basal level. #P < 0.05 as compared with thrombin-treated group.
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siRNA also reduced thrombin-induced HO-1 expression
(Figure 3B). We directly measured the PKCδ phosphoryla-
tion response to thrombin. Stimulation of OASFs with
thrombin led to a significant increase in phosphorylation
of PKCδ (Figure 3D). The PKCδ activity in OASFs was
increased by thrombin treatment in a dose-dependent
manner (Figure 3E). Pretreatment of cells with PPACK or
transfection of cells with PAR1 and PAR3 siRNA
also reduced thrombin-mediated PKCδ kinase activity
(Figure 3F). Based on these results, thrombin appears to
act through a PAR1/PAR3 and PKCδ-dependent signaling
pathway to enhance HO-1 expression in human synovial
fibroblasts.
PKCδ-dependent c-Src activation is involved in the
regulation of COX-2 expression [30], and we investi-
gated the role of Src in mediating thrombin-induced
HO-1 expression with the specific Src inhibitor PP2. As
shown in Figure 4A and 4B, thrombin-induced HO-1
expression was markedly attenuated by pretreatment of
cells for 30 minutes with PP2 or by transfection of cells
for 24 hours with c-Src mutant. The major phosphoryla-
tion site of c-Src at the Tyr416 residue results in activa-
tion of c-Src autophosphorylation [31]. To examine
directly the crucial role of c-Src in HO-1 expression, we
measured the level of c-Src phosphorylation at Tyr416 in
response to thrombin. As shown in Figure 4C, treatment
of OASFs with thrombin resulted in a time-dependent
phosphorylation of c-Src at Tyr416. Pretreatment of cells
with PPACK and rottlerin markedly inhibited the
thrombin-induced c-Src kinase activity (Figure 4D).
Based on these results, thrombin appears to act through
a signaling pathway involving the PAR1/PAR3 receptor,
PKCδ, and c-Src to enhance HO-1 expression in human
synovial fibroblasts.
Involvement of Nrf2 in thrombin-induced HO-1
expression
Activation of Nrf2 has been reported to play an important
role in HO-1 expression [32]. To determine the role of
Nrf2 in thrombin-mediated HO-1 expression, OASFs
were transfected with Nrf2 siRNA. Transfection of cells
with Nrf2 siRNA suppressed the thrombin-induced HO-1
expression (Figure 5A). Stimulation of cells with thrombin
also induced Nrf2 phosphorylation in a time-dependent
manner (Figure 5B). Pretreatment of cells with
GF109203X, rottlerin, and PP2 attenuated thrombin-
induced Nrf2 activation (Figure 5C).
We next investigated whether Nrf2 binds to the ARE
element on the HO-1 promoter after thrombin stimula-
tion. The in vivo recruitment of Nrf2 to the HO-1 pro-
moter (-857 to -752) was assessed with chromatin
immunoprecipitation assays. In vivo binding of Nrf2 to
the ARE element of the HO-1 promoter occurred after
thrombin stimulation (Figure 6A). The binding of Nrf2
to the ARE element by thrombin was attenuated by
GF109203X, rottlerin, and PP2 (Figure 6A).
Figure 4 c-Src is involved in thrombin-induced HO-1 expression in synovial fibroblasts. (A, B) Osteoarthritis synovial fibroblasts (OASFs)
(six OA lines) were pretreated for 30 minutes with PP2 (3 μM) or transfected with c-Src mutant for 24 hours followed by stimulation with
thrombin for 24 hours, and the HO-1 expression was examined with qPCR and Western blotting. (C) OASFs (five OA lines) were incubated with
thrombin for indicated time intervals, and c-Src phosphorylation was examined with Western blotting. (D) Cells (six OA lines) were pretreated 30
minutes with PPACK or rottlerin, followed by stimulation with thrombin for 30 minutes, and c-Src phosphorylation was examined with Western
blotting. Results are expressed as the mean ± SEM. *P < 0.05 as compared with basal level. #P < 0.05 as compared with thrombin-treated group.
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Figure 5 Thrombin induced Nrf2 activation in synovial fibroblasts. (A) Osteoarthritis synovial fibroblasts (OASFs; six OA lines) were
transfected with Nrf2 siRNA for 24 hours, and HO-1 expression was examined with qPCR. (B) OASFs (six OA lines) were incubated with thrombin
for indicated time intervals, and Nrf2 phosphorylation was examined with Western blotting. (C) Cells (five OA lines) were pretreated 30 minutes
with PPACK, rottlerin, or PP2 followed by stimulation with thrombin for 30 minutes, and Nrf2 phosphorylation was examined with Western
blotting. Results are expressed as the mean ± SEM. *P < 0.05 as compared with basal level. #P < 0.05 as compared with thrombin-treated group.
Figure 6 PAR, PKCδ, and c-Src are involved in thrombin-induced Nrf2 activation. (A) Osteoarthritis synovial fibroblast (OASFs; seven OA
lines) were pretreated with GF109203X, rottlerin, and PP2 for 30 minutes followed by stimulation with thrombin for 120 minutes, and ChIP assay
was then performed. Chromatin was immunoprecipitated with anti-Nrf2 antibody. One percent of the precipitated chromatin was assayed to
verify equal loading (Input). OASFs (eight OA lines) were incubated with thrombin for 24 hours (B) or pretreated with PPACK, GF109203X,
rottlerin, and PP2 for 30 minutes (C) or co-transfected with PAR1 siRNA, PAR3 siRNA, PAR4 siRNA, PKCδ siRNA, and c-Src mutant for 24 hours (D)
before incubation with thrombin for 24 hours. HO-1 luciferase activity was then assayed. Results are expressed as the mean ± SEM. *P < 0.05 as
compared with basal level. #P < 0.05 as compared with thrombin-treated group. (E) Schematic diagram of the signaling pathways involved in
thrombin-induced HO-1 expression in OASFs. Thrombin increases HO-1 expression by binding to the PAR1/PAR3 receptor and activating PKCδ
and c-Src, which enhances binding of Nrf2 to the ARE site. This results in the transactivation of HO-1 expression.
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To study further the pathways involved in the action of
thrombin-induced HO-1 expression, transient transfection
was performed by using the human HO-1 promoter-luci-
ferase construct. Treatment of cells with thrombin led to
dose-dependent increases in HO-1 promoter activity
(Figure 6B). PPACK, GF109203X, rottlerin, and PP2;
PAR1, PAR3, and PKCδ siRNA; and c-Src mutant all
antagonized the stimulation of HO-1 promoter activity by
thrombin (Figure 6C, D). These results indicated that
thrombin-induced HO-1 expression is mediated through
the PAR1/PAR3, PKCδ, c-Src, and Nrf2 pathways in
OASFs.
Discussion
OA is a heterogeneous group of conditions associated
with defective integrity of articular cartilage and related
changes in the underlying bone. The chronic inflamma-
tory process is mediated through a complex cytokine net-
work. It is not yet completely understood which factors
are responsible for initiating the degradation and loss of
articular tissues. It has been shown that thrombin acts as
a mitogen to stimulate the abnormal proliferation of
synovial cells during RA and OA pathogenesis [14,15].
We hypothesized that thrombin is highly expressed dur-
ing OA pathogenesis and promotes the release of inflam-
matory cytokines as well as increased HO-1 production
(an endogenous compensation mechanism). First, we
confirmed that synovial fluid concentrations of thrombin
were significantly higher in patients with OA than in nor-
mal fluid samples. We then identified HO-1 as a target
protein for the thrombin-signaling pathway in OASF
cells. Our results provided evidence that thrombin pro-
motes the endogenous compensation mechanism (that is,
HO-1 expression), during OA pathogenesis. We found
that thrombin increased HO-1 production (the antiin-
flammatory response); however, this mechanism is insuf-
ficient to arrest the progress of OA. Nonetheless, the
discovery of the HO-1 signaling pathway may help us to
develop effective therapy in the future.
Thrombin is known to activate three PARs, including
PAR1, PAR3, and PAR4 [33]. However, we demon-
strated that PAR1 and PAR3 but not PAR4 receptors
were required for thrombin-induced HO-1 production.
Treatment with PAR1 or PAR3 agonist induced HO-1
expression, but PAR4 agonist failed to upregulate HO-1
expression. Furthermore, we could not inhibit throm-
bin-induced HO-1 upregulation by PAR4 receptor-speci-
fic siRNA. These data suggest that PAR1 and PAR3
receptors are involved in thrombin-induced HO-1
expression in human synovial fibroblasts.
Several isoforms of PKC have been characterized at the
molecular level and have been found to mediate a variety
of cellular molecular responses [34]. We demonstrated
that the PKC inhibitor GF109203X antagonizes the
thrombin-mediated potentiation of HO-1 expression,
suggesting that PKC activation is an obligatory event in
thrombin-induced HO-1 expression in these cells. In
addition, rottlerin but not Ro320432 also inhibited
thrombin-induced HO-1 expression.
One current report indicates that rottlerin is not a
specific PKCδ inhibitor but inhibits many other targets
[35]. Therefore, we used PKCδ siRNA to confirm PKCδ
function in OASFs. We found that PKCδ siRNA inhib-
ited the enhancement of HO-1 expression. Incubation
of synovial fibroblasts with thrombin also increased
PKCδ phosphorylation and kinase activity. Conversely,
PPACK and PAR1 or PAR3 siRNA reduced thrombin-
mediated PKC kinase activity. These data suggest that
the PAR1/PAR3 and PKCδ pathways are required for
thrombin-induced HO-1 expression.
Src, a tyrosine kinase, plays a critical role in the induc-
tion of chemokine transcription [36]. Because c-Src is a
downstream effector of PKCδ [30], we examined the
potential role of c-Src in the signaling pathway of throm-
bin-induced HO-1 expression. Treatment of cells with c-
Src inhibitor PP2 or transfection of cells with c-Src
mutant reduced thrombin-mediated HO-1 expression. In
addition, we found that treatment of OASFs with throm-
bin promoted increases in c-Src phosphorylation. These
effects were inhibited by PPACK and rottlerin, indicating
the involvement of PKCδ-dependent c-Src activation in
thrombin-mediated HO-1 induction.
Several binding sites exist for a number of transcrip-
tion factors, including ARE in the 5’ promoter region of
the HO-1 gene [37]. The results of this study show that
Nrf2 activation contributes to thrombin-induced HO-1
production in synovial fibroblasts, and that inhibition of
the Nrf2-dependent signaling pathway, including Nrf2
siRNA, inhibits thrombin-induced HO-1 expression. We
found that treatment of synovial fibroblasts with throm-
bin resulted in increased Nrf2 phosphorylation. Further-
more, thrombin increased the binding of Nrf2 to the
ARE element within the HO-1 promoter, as shown by a
chromatin immunoprecipitation assay. Binding of Nrf2 to
the ARE element was attenuated by GF109203X, rottlerin,
and PP2. By using transient transfection with HO-1-luci-
ferase as an indicator of HO-1 activity, we also found that
thrombin induced an increase in HO-1 activity. In addi-
tion, PPACK, GF109203X, rottlerin, and PP2 reduced
thrombin-increased HO-1 promoter activity. Based on
these findings, we propose that the PAR1/PAR3, PKCδ,
and c-Src pathways are involved in thrombin-induced
Nrf2 activation in human synovial fibroblasts.
Conclusions
We explored the signaling pathways involved in throm-
bin-induced HO-1 expression in human synovial fibro-
blasts. We found that thrombin augmented HO-1
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expression by binding to the PAR1/PAR3 receptor and
activating PKCδ and c-Src, which enhanced binding of
Nrf2 to the ARE site and resulted in HO-1 expression
(Figure 6E). The discovery of this HO-1 signaling pathway
helps us to understand the mechanism of OA pathogen-
esis and may lead us to develop effective therapy in the
future.
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